Late stent thrombosis after implantation of a sirolimus-eluting stent.

Late stent thrombosis in the era of routine high-pressure stent deployment and combined antiplatelet therapy with thienopyridines and aspirin has become a rare but feared complication. We describe a patient with acute myocardial infarction due to late stent thrombosis 6 weeks after deployment of a sirolimus-eluting stent and 2 weeks after the discontinuation of clopidogrel. This is the first report of late thrombosis of a sirolimus-eluting stent.     

Late stent thrombosis thirteen months after drug-eluting stent implantation

We present a case of a very late stent thrombosis which occurred 13 months after drug-eluting stent (DES) implantation. The DES was off-label used in a high-risk patient and was followed by 12-month clopidogrel administration. One month after the drug discontinuation the stent thrombosis occurred, resulting in acute myocardial infarction. The patient was successfully treated with balloon coronary angioplasty and was advised to use clopidogrel indefinitely.     

Coronary artery aneurysm formation after drug-eluting stent implantation

Drug-eluting stents (DES) have had a profound impact on the practice of interventional cardiology. Important safety concerns regarding DES have been widely publicized and acknowledged. The primary emphasis has been placed on late stent thrombosis and the adverse sequela which result. Another emerging adverse effect of DES is coronary aneurysm (CAA) formation. We report on a patient who developed CAA formation after DES implantation but not at the site of previous bare-metal stent (BMS) implantation. We also review the current understanding of DES-associated CAA formation.     

Late stent thrombosis associated with coronary aneurysm formation after sirolimus-eluting stent implantation

Stent thrombosis is a rare but potentially fatal complication of coronary stent implantation. Its occurrence late after drug-eluting stent (DES) deployment has led to concerns regarding their long-term safety. We report a case of late stent thrombosis 26 months after sirolimus-eluting stent (SES) (Cypher, Cordis Corp., Miami, Florida) implantation. This was associated with marked positive vessel remodeling and coronary aneurysm formation involving the stented segment of the coronary artery. The patient was on dual antiplatelet therapy at the time.     

Simultaneous two-vessel very late stent thrombosis and coronary aneurysm formation after sirolimus-eluting stent implantation: an intravascular ultrasound evaluation

Very late stent thrombosis is a rare but devastating complication. Several factors are known to contribute to its occurrence, and are related to the patient, procedure, lesion and premature discontinuation of antiplatelet therapy. This report describes the case of a 49-year-old patient with simultaneous two-vessel stent thrombosis (left anterior descending and circumflex arteries) 24 months after sirolimus-eluting stent implantation. The importance of intravascular ultrasound is enhanced. The potential contributing factors to the stent thrombosis are analyzed.     

Initial clinical results with the Wiktor stent: a new balloon-expandable coronary stent

The Wiktor stent, a new coronary balloon-expandable tantalum stent, was implanted in 17 patients for other wise nonmanageable occlusion after balloon angioplasty (n = 11) and for recurrent restenosis (n = 6). Stents of 3.0 to 4.0 mm were implanted (right coronary artery: n = 10, left anterior descending artery: n = 4, left circumflex artery: n = 2, venous graft: n = 1). All patients were fully anticoagulated initially with heparin followed by coumadin for 3 months and were treated with acetylsalicylic acid indefinitely. Due to its good radiopacity, the device could be placed easily without complications. Early occlusion occurred in one patient after 8 h probably due to friable atheromatous material prolapsing between the meshes of the stent. Late occlusion occurred in another patient who was admitted in cardiogenic shock after pre-hospital reanimation and was stented after occlusive disection following balloon angioplasty of an occluded right coronary artery. In this patient with severe hypoxic brain damage, reocclusion and reinfarction to which the patient finally succumbed occurred following cessation of anticoagulation. Histology demonstrated occlusive thrombosis without evidence of a neointimal covering of the stent. Another thrombotic occlusion due to inadvertent omission of anticoagulation occurred in another patient two weeks after stenting. Control angiography after 6 months in 12 patients revealed restenosis in two patients (50% and 80%). The patient with 80% restenosis of the right coronary artery and pathologic results during stress testing underwent surgical revascularization. The other patient with a 50% restenosis of the right coronary artery was managed medically as he was asymptomatic and without evidence of ischemia during stress testing.(ABSTRACT TRUNCATED AT 250 WORDS)     

Very late stent thrombosis after sirolimus-eluting stent implantation observed using optical coherence tomography and coronary angioscopy

Sirolimus-eluting stents (SES) are now commonly used for percutaneous coronary intervention (PCI) because they dramatically reduce the rates of restenosis and target lesion revascularization, even in small vessels and long lesions as compared with bare-metal stent. The unresolved issue about SES use is the possibility of late stent thrombosis. Late stent thrombosis is a very rare, but serious complication that may result in acute myocardial infarction or sudden cardiac death. However, the mechanism of late stent thrombosis with SES has not been established. We report a patient with very late stent thrombosis 37 months after SES implantation who underwent optical coherence tomography and coronary angioscopy.     

Acute and mid-term experiences with the Wiktor stent in acute complications and restenosis after coronary angioplasty

We report about the 6-month follow-up of 28 consecutive patients treated with a new tantalum stent (Wiktor? stent, Medtronic, Inc.). Indication for stenting was the prevention of restenosis in eight patients (restenosis group), and threatening or acute closure after PTCA in 20 patients (acute closure group). Twenty-eight of 30 stents were successfully positioned in 27 of 28 patients (96%), whereas implantation failed twice in one patient. Immediate stent occlusion developed in two patients in the acute closure group (7.4%). Subacute stent occlusion was observed in three patients (11%), one in the restenosis group, two in the acute closure group, between 3 and 5 days after implantation. Coronary bypass surgery had to be performed in four patients (15%): one patient after failed stent placement, two after acute, and one after subacute stent thrombosis. Major bleeding complications related to the anticoagulative drug regimen occurred in nine patients (33%). Three patients (11%) died for reasons most probably not related to stent implantation. A 6-month angiographic follow-up revealed restenosis in two of 19 patients (11%), one patient in each group. Sixteen of the 27 stented patients (59%) reached 6-month follow-up without death, acute or subacute stent thrombosis, or restenosis. It is concluded that the Wiktor stent can be placed with a high rate of success. It may also reduce the risk of restenosis. The stent also offers the possibility to circumvent emergency bypass surgery in case of PTCA related vessel occlusion. Acute and subacute stent occlusion still remains an unsolved topic.     

A case of recurrent stent thrombosis in a drug-eluting stent following antiplateled therapy discontinuation

Stent thrombosis is one of the major complications that occur in percutaneous coronary interventions with stents. Various factors have been attributed to the development of stent thrombosis and several strategies have been recommended for its management. We report a case of 45 year-old patient with recurrent subacute and late stent thrombosis following antiplateled therapy discontinuation on the 6th day and 11th month after he discharging from hospital.     

The conundrum of late and very late stent thrombosis following drug-eluting stent implantation

PURPOSE OF REVIEW: Drug-eluting stents reduce restenosis compared with bare metal stents, but there is growing concern that drug-eluting stents may lead to higher rates of late stent thrombosis, a rare and potentially catastrophic complication following stenting. RECENT FINDINGS: While the data on the risk of late stent thrombosis are not definitive, several general conclusions may be drawn from the available data. Late thrombosis, while associated with high mortality and morbidity, is an uncommon complication of both drug-eluting stents and bare metal stents. Randomized trials of approved drug-eluting stents versus bare metal stents have shown additional cases of late stent thrombosis in drug-eluting stents, but no significant difference in the cumulative incidence of stent thrombosis, myocardial infarction, or cardiac death at 4 years of follow-up. Observational studies suggest higher very late stent thrombosis incidence, but the relative risks of drug-eluting stents versus bare metal stents in specific high-risk groups require further study. Although the etiology of late stent thrombosis is multifactorial, premature discontinuation of clopidogrel appears to be the most important risk factor. SUMMARY: Long-term follow-up of patients after coronary stenting has identified stent thrombosis as a rare but serious event. Ongoing clinical trials in broader patient populations will be helpful to understand the risk of late stent thrombosis with greater certainty.     

Bare-metal stent thrombosis two decades after stenting

Very late bare-metal stent (BMS) thrombosis is unusual in clinical practice. To the best of our knowledge, the latest that the thrombosis of a BMS has been reported is 14 years after implantation. Here, we describe a case of BMS thrombosis that occurred two decades after stenting. A 68-year-old male patient was admitted with acute anterior myocardial infarction. This patient had a history of BMS implantation in the left anterior descending coronary artery (LAD) 20 years previously. Immediate coronary angiography demonstrated acute thrombotic occlusion of the stent in the LAD. With this case, we are recording the latest reported incidence of BMS thrombosis after implantation.     

Bare metal stent thrombosis 13 years after implantation

There has been a great deal of recent controversy regarding the risk of very late stent thrombosis with drug eluting stents, especially in the context of antiplatelet therapy cessation. We report a case of very late stent thrombosis of a bare metal stent initially implanted for treatment of a myocardial infarction. The patient presented thirteen years later with a recurrent myocardial infarction three days after discontinuing aspirin. Angiography demonstrated thrombotic occlusion and severe underlying restenosis of the stent. To our knowledge, this is the latest bare metal stent thrombosis described in the world medical literature.     

Recurrent very late stent thrombosis after bare-metal stent implantation.

Very late bare-metal stent thrombosis occurring beyond 1 year after stenting is uncommon. Although much attention has been paid for late stent thrombosis, long-term outcome of patients who developed late stent thrombosis is not clear. We report a case of recurrent very late stent thrombosis after bare-metal stent implantation.     

Late coronary stent thrombosis: early vs. late stent thrombosis in the stent era.

The incidence of coronary stent thrombosis is < 1%-2% in recent studies, with the highest-risk period considered to be the first 30 days following stent implantation. Recently, stent thrombosis after 30 days has been reported in patients undergoing brachytherapy with stenting. We reviewed the incidence of stent thrombosis causing myocardial infarction in nonbrachytherapy patients at our institution between 1 January 1996 and 30 November 1999. A case control methodology was employed with a 1:3 ratio of stent thrombosis to control patients. Of 1,191 patients undergoing coronary stenting, acute (< 24 hr) plus subacute (1-30 days) stent thrombosis occurred in 0.92% (11 of 1,191 patients). A further 0.76% (9 of 1,191 patients) developed late stent thrombosis after 30 days. There were no clinical or angiographic features at the time of the initial procedure that were associated with stent thrombosis as an entire group compared with control group, but early (acute and subacute) stent thrombosis patients had a smaller final stent minimal lumen diameter and longer stent length compared with patients who had late stent thrombosis or controls. Late stent thrombosis occurs in nonbrachytherapy patients and is almost as frequent as early stent thrombosis. Further studies are required to determine whether longer-term poststent pharmacological treatment may decrease or prevent this complication.     

Recurrent coronary stent thrombosis

A 63-year-old woman with an acute anterior myocardial infarction was treated with primary stent implantation. The absence of coronary artery stenosis and an haematocrit of 58 were indicative of a myeloproliferative disorder and the diagnosis of polycythaemia vera (Vaquez' disease) was confirmed by bone marrow aspiration. The patient had a re-infarction 8 days later. A rescue percutaneous angioplasty was performed for stent thrombosis after unsuccessful thrombolysis. A few hours after sheath removal, a femoral artery thrombosis at the puncture side needed urgent thrombectomy. Finally, a second re-infarction occurred, followed by an irreversible cardiac arrest. Stent thrombosis is a difficult-to-treat complication in patients with polycythaemia vera. If this haematologic disorder is known, primary stent implantation for acute myocardial infarction may not be the first choice in these patients.     

Very late stent thrombosis in late stent malapposition after sirolimus-eluting stent implantation

Late stent malapposition (LSM) has been demonstrated to be more common after drug-eluting stent (DES) implantation than after bare-metal stent (BMS) implantation. To date, this unusual intravascular ultrasonic finding after DES implantation, however, has not received enough attention, because previous studies suggested few adverse clinical sequelae from LSM. We present a case of angiographically-confirmed very late stent thrombosis (ST) in LSM after elective implantation of sirolimus-eluting stents. In this 32-year-old male patient, very late ST occurred at 29 months after DES implantation and at 20 months after the identification of LSM. Although this patient had received sufficient dual antiplatelet therapy with aspirin and clopidogrel for more than 1 year, he suffered from ST shortly after the discontinuation of clopidogrel. Thus, patients with LSM may pose a significant risk for very late ST after discontinuation of dual antiplatelet therapy. The findings suggest that dual antiplatelet therapy should be further prolonged in patients with LSM.     

复杂冠状动脉病变西罗莫司洗脱支架置入后急性和亚急性支架内血栓形成情况分析

目的评价在真实临床环境下,对于复杂病变置入西罗莫司(雷帕霉素)洗脱支架后支架内急性、亚急性血栓的发生率。方法我院自2002年到2005年3月,连续有796名不同复杂冠状动脉(冠脉)病变的患者完全置入了西罗莫司洗脱支架(sirolimus-eluting stent,SES)。记录患者的一般临床特征和有否急性、亚急性血栓形成;所有患者平均临床随访6~9个月,随访期间对患者进行冠脉造影检查。结果(1)在796例患者中,有8例(1%,8/796)患者发生了经冠脉造影证实的急性/亚急性血栓,其中1例为急性支架内血栓形成,7例为亚急性支架内血栓形成;有1例临床高度怀疑为支架内亚急性血栓形成;(2)上述8例患者中有3例表现为急性ST段抬高的心肌梗死,4例表现为急性非ST段抬高的心肌梗死,1例表现为不稳定型心绞痛;1例高度怀疑支架内血栓形成的患者ECG表现为新发左束支传导阻滞;8例患者中有1例(12.5%,1/8)在30 d内死亡,其余7例患者给予积极治疗后6个月临床随访无不良心脏事件发生,6个月冠脉造影随访支架内没有发生再狭窄;(3)采用多因素逻辑回归分析结果显示分叉病变双支架置入及长病变支架置入是患者术后发生支架内血栓的危险因素,OR值分别为11.2和8.6,95%CI分别为4.1~30.8和1.9~17.2,P<0.001。结论在真实临床环境下,在没有经过严格入选标准筛选的复杂冠脉病变中置入SES支架后30 d内,支架内血栓的发生率在1%(8/796)左右,略高于文献报道的结果。分叉病变双支架及长病变支架是术后支架内发生血栓的高危因素。     

Recurrence of late-acquired incomplete stent apposition following sirolimus-eluting stent implantation

Stent thrombosis has been recognized as a potentially critical complication in percutaneous coronary intervention. In the bare-metal stent era, stent thrombosis was considered to be an acute or subacute event, occurring within 1 month after stent implantation. Recently, late or very late stent thrombosis after drug-eluting stent implantation has been brought into focus; however, the mechanism underlying this potentially fatal event is largely unknown. We report a case of critical late thrombosis 2 years after sirolimus-eluting stent implantation. Detailed serial intravascular ultrasound analyses revealed that late-acquired incomplete stent apposition, accompanied by extensive positive vascular remodeling, was involved in the pathogenesis of the nearly fatal event described in this case.     

Stent-related cardiac events after non-cardiac surgery: drug-eluting stent vs. bare metal stent

For evaluation of post-operative stent associated cardiac events after drug-eluting stent (DES) implantation we analyzed data of 138 patients who underwent non-cardiac surgery after DES implantation and compared the data with those of 101 patients who underwent non-cardiac surgery after bare metal stent (BMS) implantation. Three patients (2.2%) in DES group developed post-operative cardiac events and none in BMS group (p=0.2). One patient died due to suspected stent thrombosis and the other two had myocardial infarction due to angiographically proven stent thrombosis. The time interval between stent implantation and surgery in those with cardiac events was 6, 264, and 367 days, respectively. Our data shows that peri-operative stent-related thrombotic complications can occur long after DES implantation and careful peri-operative monitoring for cardiac events is needed in patients receiving non-cardiac surgery after DES implantation.     

Drug-eluting stent thrombosis after cilostazol withdrawal in a patient previously treated with triple antiplatelet therapy

Antiplatelet therapy has been shown to reduce cardiac events after coronary stenting. However, despite aggressive antiplatelet therapy, stent thrombosis remains a serious complication of coronary stenting with drug-eluting stent (DES). Although several predictors for DES thrombosis have been suggested by investigators, this serious condition is still not completely preventable now. In particular, patients undergoing non-cardiac surgery or invasive procedures with bleeding risk may interrupt antiplatelet therapy and occasionally experience stent thrombosis. We report a case of DES thrombosis after cilostazol withdrawal for colonoscopic polypectomy in a patient previously treated with triple antiplatelet therapy. The patient presented with acute myocardial infarction but survived after successful emergency coronary revascularization. We discuss a plausible mechanism for DES thrombosis in the described case.